New York State Teachers Retirement System Has $9.02 Million Holdings in DaVita Inc. (NYSE:DVA)

New York State Teachers Retirement System trimmed its stake in shares of DaVita Inc. (NYSE:DVA - Free Report) by 8.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 55,032 shares of the company's stock after selling 5,112 shares during the quarter. New York State Teachers Retirement System owned about 0.06% of DaVita worth $9,021,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the stock. Sumitomo Mitsui Trust Holdings Inc. lifted its position in DaVita by 1.6% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 134,823 shares of the company's stock worth $18,612,000 after purchasing an additional 2,129 shares during the period. First Trust Direct Indexing L.P. lifted its holdings in shares of DaVita by 3.9% in the first quarter. First Trust Direct Indexing L.P. now owns 2,590 shares of the company's stock valued at $358,000 after buying an additional 98 shares during the period. Janney Montgomery Scott LLC boosted its stake in DaVita by 175.5% during the first quarter. Janney Montgomery Scott LLC now owns 18,937 shares of the company's stock valued at $2,614,000 after buying an additional 12,064 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. grew its holdings in DaVita by 11.9% during the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 2,377 shares of the company's stock worth $328,000 after acquiring an additional 253 shares during the period. Finally, Quent Capital LLC raised its position in DaVita by 21.0% in the first quarter. Quent Capital LLC now owns 581 shares of the company's stock worth $80,000 after acquiring an additional 101 shares in the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DVA has been the subject of several recent research reports. Truist Financial increased their target price on shares of DaVita from $165.00 to $175.00 and gave the company a "hold" rating in a research note on Monday, October 7th. TD Cowen raised their price objective on DaVita from $139.00 to $150.00 and gave the stock a "hold" rating in a research note on Wednesday, July 24th. Bank of America boosted their target price on DaVita from $139.00 to $145.00 and gave the stock an "underperform" rating in a research report on Wednesday, August 7th. Barclays increased their price target on DaVita from $150.00 to $164.00 and gave the company an "equal weight" rating in a research report on Thursday. Finally, UBS Group boosted their price objective on DaVita from $169.00 to $175.00 and gave the stock a "buy" rating in a report on Thursday, August 8th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $161.80.

DaVita Stock Up 2.4 %

NYSE:DVA traded up $3.35 during trading hours on Monday, hitting $144.94. 810,589 shares of the company's stock traded hands, compared to its average volume of 820,010. DaVita Inc. has a twelve month low of $78.05 and a twelve month high of $168.50. The firm has a market cap of $11.89 billion, a P/E ratio of 15.64, a P/E/G ratio of 0.79 and a beta of 0.89. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.12 and a current ratio of 1.37. The stock's fifty day moving average price is $157.71 and its two-hundred day moving average price is $146.30.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company had revenue of $3.26 billion during the quarter, compared to analysts' expectations of $3.25 billion. During the same period last year, the company earned $2.85 earnings per share. DaVita's revenue for the quarter was up 4.6% compared to the same quarter last year. On average, research analysts expect that DaVita Inc. will post 9.73 earnings per share for the current fiscal year.

Insider Buying and Selling at DaVita

In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the company's stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total value of $1,148,771.97. Following the transaction, the insider now directly owns 83,011 shares of the company's stock, valued at $12,137,038.31. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, insider Kathleen Alyce Waters sold 7,857 shares of the firm's stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the transaction, the insider now owns 83,011 shares in the company, valued at approximately $12,137,038.31. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Michael David Staffieri sold 9,539 shares of the stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the transaction, the chief operating officer now directly owns 241,945 shares in the company, valued at $36,299,008.35. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 173,482 shares of company stock valued at $27,387,069 in the last quarter. Company insiders own 2.00% of the company's stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.